Literature DB >> 20827161

In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.

Charlotte Charpentier1, Lucile Larrouy, Gilles Collin, Florence Damond, Sophie Matheron, Geneviève Chêne, Ting Nie, Raymond Schinazi, Françoise Brun-Vézinet, Diane Descamps.   

Abstract

In this study of nine clinical isolates obtained from integrase inhibitor-naïve HIV-2-infected patients, the median EC₅₀ value for the new integrase inhibitor S/GSK1349572 was 0.8 nM (range 0.2-1.4), and is similar to HIV-1 reference strains. We found a seven-, 13- and 18-fold increase in EC₅₀ values to S/GSK1349572 for the HIV-2 double (T97A + Y143C; G140S + Q148R) and triple (G140T + Q148R + N155H) mutants, respectively, obtained from two raltegravir-experienced patients.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20827161     DOI： 10.1097/QAD.0b013e32833f9e36

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.632


  14 in total

1.  In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Authors:  Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

2.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Sally S Leong; Kate M Parker; Mariah K Oakes; Papa Salif Sow; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

4.  A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.

Authors:  Selly Ba; Dana N Raugi; Robert A Smith; Fatima Sall; Khadim Faye; Stephen E Hawes; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

5.  Genotypic resistance profiles of HIV-2-treated patients in West Africa.

Authors:  Charlotte Charpentier; Serge Eholié; Xavier Anglaret; Mélanie Bertine; Christine Rouzioux; Véronique Avettand-Fenoël; Eugène Messou; Albert Minga; Florence Damond; Jean-Christophe Plantier; François Dabis; Gilles Peytavin; Françoise Brun-Vézinet; Didier K Ekouevi
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

6.  Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.

Authors:  Philip L Tzou; Diane Descamps; Soo-Yon Rhee; Dana N Raugi; Charlotte Charpentier; Nuno Taveira; Robert A Smith; Vicente Soriano; Carmen de Mendoza; Susan P Holmes; Geoffrey S Gottlieb; Robert W Shafer
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

7.  In Vitro Antiviral Activity of Cabotegravir against HIV-2.

Authors:  Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

8.  HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase.

Authors:  Agnès Depatureaux; Peter K Quashie; Thibault Mesplède; Yingshan Han; Hannah Koubi; Jean-Christophe Plantier; Maureen Oliveira; Daniela Moisi; Bluma Brenner; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

9.  Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.

Authors:  Robert A Smith; Dana N Raugi; Charlotte Pan; Matthew Coyne; Alexandra Hernandez; Brad Church; Kara Parker; James I Mullins; Papa Salif Sow; Geoffrey S Gottlieb
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

10.  HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.

Authors:  Geoffrey S Gottlieb; Robert A Smith; Ndeye Mery Dia Badiane; Selly Ba; Stephen E Hawes; Macoumba Toure; Alison K Starling; Fatou Traore; Fatima Sall; Stephen L Cherne; Joshua Stern; Kim G Wong; Paul Lu; Moon Kim; Dana N Raugi; Airin Lam; James I Mullins; Nancy B Kiviat
Journal:  PLoS One       Date:  2011-07-12       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.